id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0024,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Assessing User Fees Under the Generic Drug User Fee Amendments of 2017,Other,Guidance,2017-10-30T04:00:00Z,2017,10,2017-10-30T04:00:00Z,,2022-05-19T15:23:06Z,,0,0,0900006482c22925
FDA-2012-D-0880-0023,FDA,FDA-2012-D-0880,"Assessing User Fees Under the Generic Drug User Fee Amendments of 
2017; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-10-30T04:00:00Z,2017,10,2017-10-30T04:00:00Z,2017-12-30T04:59:59Z,2017-12-29T02:00:42Z,2017-23526,0,0,0900006482c21d18
FDA-2012-D-0880-0021,FDA,FDA-2012-D-0880,"Generic Drug User Fee Amendments of 2012: Questions and Answers Related to Self-Identification of Facilities, Review of Generic Drug Submissions, and Inspections and Compliance; Guidance for Industry; Availability",Notice,Notice of Availability,2017-07-26T04:00:00Z,2017,7,2017-07-26T04:00:00Z,,2017-07-26T13:59:13Z,2017-15654,0,0,090000648296a012
FDA-2012-D-0880-0022,FDA,FDA-2012-D-0880,Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments Guidance for Industry,Other,Guidance,2017-07-26T04:00:00Z,2017,7,2017-07-26T04:00:00Z,,2024-11-07T01:03:50Z,,1,0,090000648296d644